BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BioCentury | Mar 13, 2019
Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture studies suggest inhibiting IKK or its scaffold protein NEMO in combination with inhibition of MC-1 could help treat STK11-deficient lung cancer. In a human STK11-deficient lung cancer cell line, the...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Hepatic

...inhibitor of κ light gene enhancer in B cells kinase α (IKKα; IKBKA; IKK1; CHUK; NFKBIKA...
...CONTACT: Liangyou Rui, University of Michigan Medical School, Ann Arbor, Mich. email: ruily@umich.edu Claire Quang University of Michigan Inhibitor of kappa light gene enhancer in B cells kinase alpha (IKKalpha) (IKBKA) (IKK1) (CHUK) (NFKBIKA) MAP...
BioCentury | Apr 13, 2018
Preclinical News

NCI identifies new lymphoma subtypes

A New England Journal of Medicine paper out of NIH's National Cancer Institute revealed new subtypes of diffuse large B cell lymphomas (DLBCL) that could lead to more targeted therapeutic strategies. The report adds to...
BioCentury | Apr 10, 2018
Distillery Therapeutics

Cancer

...Inhibitor of κ light gene enhancer in B cells kinase α (IKKα; IKBKA; IKK1; CHUK; NFKBIKA...
...Greece email: gstathop@upatras.gr CONTACT: Antonia Marazioti, same affiliation as above email: amarazioti@upatras.gr Jaime De Leon University of Patras Inhibitor of kappa light gene enhancer in B cells kinase alpha (IKKalpha) (IKBKA) (IKK1) (CHUK) (NFKBIKA) K-Ras...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 21, 2017
Preclinical News

New tool for degradation of endogenous proteins

...cell line. Additionally, co-electroporation of exogenous TRIM21 and antibodies against inhibitor of kappa light gene enhancer in B cells kinase alpha (IKKalpha; IKBKA; IKK1; CHUK; NFKBIKA...
...Research Council Laboratory of Molecular Biology (MRC LMB) National Institute of Health Sciences Takeda Pharmaceutical Co. Ltd. Huntingtin (HTT) Inhibitor of kappa light gene enhancer in B cells kinase alpha (IKKalpha) (IKBKA) (IKK1) (CHUK) (NFKBIKA) MAP...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest depleting microglia or inhibiting their inflammatory activity could help treat obesity. In a mouse model of obesity, depletion of microglia in the mediobasal hypothalamus with the CSF1R inhibitor PLX5622 or...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Items per page:
1 - 10 of 57